Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents
We prospectively investigated the changes of liver stiffness (LS) and the occurrence of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) eradication using direct antiviral agents (DAA) over three years. LS measurement using transient elastography and serum fibrosis surrogate markers befo...
Uloženo v:
| Vydáno v: | Scientific Reports Ročník 12; číslo 1; s. 193 - 9 |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
Springer Science and Business Media LLC
07.01.2022
Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Témata: | |
| ISSN: | 2045-2322, 2045-2322 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | We prospectively investigated the changes of liver stiffness (LS) and the occurrence of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) eradication using direct antiviral agents (DAA) over three years. LS measurement using transient elastography and serum fibrosis surrogate markers before treatment and at 48, 96, 144 weeks after starting direct-acting antivirals (DAA) according to the protocol were evaluated. Patients were also compared with historical cohort treated with pegylated interferon (peg-IFN). Sustained viral response (SVR) was observed in 95.8%. LS value in the patients achieving SVR significantly decreased over time (19.4 ± 12.9 kPa [baseline], 13.9 ± 9.1 kPa [48 weeks], 11.7 ± 8.2 kPa [96 weeks], 10.09 ± 6.23 [144 weeks], all
p
< 0.001). With matched analysis, the decrease in LS value was significantly larger in DAA group than peg-IFN group at both 48 weeks (29% vs. 9%) and 96 weeks (39% vs. 17%). The incidence of HCC was not significantly different between DAA and peg-IFN groups (5.5% vs. 5.4%) at 144 weeks. HCV eradication with DAA can lead to improvement of liver stiffness over time. The regression of fibrosis was greater in the group with DAA than peg-IFN.
Clinical trials registration: ClinicalTrials.gov (NCT02865369). |
|---|---|
| AbstractList | We prospectively investigated the changes of liver stiffness (LS) and the occurrence of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) eradication using direct antiviral agents (DAA) over three years. LS measurement using transient elastography and serum fibrosis surrogate markers before treatment and at 48, 96, 144 weeks after starting direct-acting antivirals (DAA) according to the protocol were evaluated. Patients were also compared with historical cohort treated with pegylated interferon (peg-IFN). Sustained viral response (SVR) was observed in 95.8%. LS value in the patients achieving SVR significantly decreased over time (19.4 ± 12.9 kPa [baseline], 13.9 ± 9.1 kPa [48 weeks], 11.7 ± 8.2 kPa [96 weeks], 10.09 ± 6.23 [144 weeks], all
p
< 0.001). With matched analysis, the decrease in LS value was significantly larger in DAA group than peg-IFN group at both 48 weeks (29% vs. 9%) and 96 weeks (39% vs. 17%). The incidence of HCC was not significantly different between DAA and peg-IFN groups (5.5% vs. 5.4%) at 144 weeks. HCV eradication with DAA can lead to improvement of liver stiffness over time. The regression of fibrosis was greater in the group with DAA than peg-IFN.
Clinical trials registration: ClinicalTrials.gov (NCT02865369). Abstract We prospectively investigated the changes of liver stiffness (LS) and the occurrence of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) eradication using direct antiviral agents (DAA) over three years. LS measurement using transient elastography and serum fibrosis surrogate markers before treatment and at 48, 96, 144 weeks after starting direct-acting antivirals (DAA) according to the protocol were evaluated. Patients were also compared with historical cohort treated with pegylated interferon (peg-IFN). Sustained viral response (SVR) was observed in 95.8%. LS value in the patients achieving SVR significantly decreased over time (19.4 ± 12.9 kPa [baseline], 13.9 ± 9.1 kPa [48 weeks], 11.7 ± 8.2 kPa [96 weeks], 10.09 ± 6.23 [144 weeks], all p < 0.001). With matched analysis, the decrease in LS value was significantly larger in DAA group than peg-IFN group at both 48 weeks (29% vs. 9%) and 96 weeks (39% vs. 17%). The incidence of HCC was not significantly different between DAA and peg-IFN groups (5.5% vs. 5.4%) at 144 weeks. HCV eradication with DAA can lead to improvement of liver stiffness over time. The regression of fibrosis was greater in the group with DAA than peg-IFN. Clinical trials registration: ClinicalTrials.gov (NCT02865369). We prospectively investigated the changes of liver stiffness (LS) and the occurrence of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) eradication using direct antiviral agents (DAA) over three years. LS measurement using transient elastography and serum fibrosis surrogate markers before treatment and at 48, 96, 144 weeks after starting direct-acting antivirals (DAA) according to the protocol were evaluated. Patients were also compared with historical cohort treated with pegylated interferon (peg-IFN). Sustained viral response (SVR) was observed in 95.8%. LS value in the patients achieving SVR significantly decreased over time (19.4 ± 12.9 kPa [baseline], 13.9 ± 9.1 kPa [48 weeks], 11.7 ± 8.2 kPa [96 weeks], 10.09 ± 6.23 [144 weeks], all p < 0.001). With matched analysis, the decrease in LS value was significantly larger in DAA group than peg-IFN group at both 48 weeks (29% vs. 9%) and 96 weeks (39% vs. 17%). The incidence of HCC was not significantly different between DAA and peg-IFN groups (5.5% vs. 5.4%) at 144 weeks. HCV eradication with DAA can lead to improvement of liver stiffness over time. The regression of fibrosis was greater in the group with DAA than peg-IFN.Clinical trials registration: ClinicalTrials.gov (NCT02865369).We prospectively investigated the changes of liver stiffness (LS) and the occurrence of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) eradication using direct antiviral agents (DAA) over three years. LS measurement using transient elastography and serum fibrosis surrogate markers before treatment and at 48, 96, 144 weeks after starting direct-acting antivirals (DAA) according to the protocol were evaluated. Patients were also compared with historical cohort treated with pegylated interferon (peg-IFN). Sustained viral response (SVR) was observed in 95.8%. LS value in the patients achieving SVR significantly decreased over time (19.4 ± 12.9 kPa [baseline], 13.9 ± 9.1 kPa [48 weeks], 11.7 ± 8.2 kPa [96 weeks], 10.09 ± 6.23 [144 weeks], all p < 0.001). With matched analysis, the decrease in LS value was significantly larger in DAA group than peg-IFN group at both 48 weeks (29% vs. 9%) and 96 weeks (39% vs. 17%). The incidence of HCC was not significantly different between DAA and peg-IFN groups (5.5% vs. 5.4%) at 144 weeks. HCV eradication with DAA can lead to improvement of liver stiffness over time. The regression of fibrosis was greater in the group with DAA than peg-IFN.Clinical trials registration: ClinicalTrials.gov (NCT02865369). We prospectively investigated the changes of liver stiffness (LS) and the occurrence of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) eradication using direct antiviral agents (DAA) over three years. LS measurement using transient elastography and serum fibrosis surrogate markers before treatment and at 48, 96, 144 weeks after starting direct-acting antivirals (DAA) according to the protocol were evaluated. Patients were also compared with historical cohort treated with pegylated interferon (peg-IFN). Sustained viral response (SVR) was observed in 95.8%. LS value in the patients achieving SVR significantly decreased over time (19.4 ± 12.9 kPa [baseline], 13.9 ± 9.1 kPa [48 weeks], 11.7 ± 8.2 kPa [96 weeks], 10.09 ± 6.23 [144 weeks], all p < 0.001). With matched analysis, the decrease in LS value was significantly larger in DAA group than peg-IFN group at both 48 weeks (29% vs. 9%) and 96 weeks (39% vs. 17%). The incidence of HCC was not significantly different between DAA and peg-IFN groups (5.5% vs. 5.4%) at 144 weeks. HCV eradication with DAA can lead to improvement of liver stiffness over time. The regression of fibrosis was greater in the group with DAA than peg-IFN. Clinical trials registration: ClinicalTrials.gov (NCT02865369). We prospectively investigated the changes of liver stiffness (LS) and the occurrence of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) eradication using direct antiviral agents (DAA) over three years. LS measurement using transient elastography and serum fibrosis surrogate markers before treatment and at 48, 96, 144 weeks after starting direct-acting antivirals (DAA) according to the protocol were evaluated. Patients were also compared with historical cohort treated with pegylated interferon (peg-IFN). Sustained viral response (SVR) was observed in 95.8%. LS value in the patients achieving SVR significantly decreased over time (19.4 ± 12.9 kPa [baseline], 13.9 ± 9.1 kPa [48 weeks], 11.7 ± 8.2 kPa [96 weeks], 10.09 ± 6.23 [144 weeks], all p < 0.001). With matched analysis, the decrease in LS value was significantly larger in DAA group than peg-IFN group at both 48 weeks (29% vs. 9%) and 96 weeks (39% vs. 17%). The incidence of HCC was not significantly different between DAA and peg-IFN groups (5.5% vs. 5.4%) at 144 weeks. HCV eradication with DAA can lead to improvement of liver stiffness over time. The regression of fibrosis was greater in the group with DAA than peg-IFN.Clinical trials registration: ClinicalTrials.gov (NCT02865369). |
| ArticleNumber | 193 |
| Author | Sae Hwan Lee Jun Yong Park Young Kul Jung Jae Young Jang Hae Won Yoo Sang Gyune Kim Moon Young Kim Jin Woo Lee Dae Won Jun Oh Sang Kwon |
| Author_xml | – sequence: 1 givenname: Hae Won surname: Yoo fullname: Yoo, Hae Won organization: Department of Internal Medicine, SoonChunHyang University School of Medicine, Digestive Disease Center and Research Institute, SoonChunHyang University Bucheon Hospital – sequence: 2 givenname: Jun Yong surname: Park fullname: Park, Jun Yong email: drpjy@yuhs.ac organization: Department of Internal Medicine, Yonsei University College of Medicine, Yonsei Liver Center, Severance Hospital – sequence: 3 givenname: Sang Gyune surname: Kim fullname: Kim, Sang Gyune email: mcnulty@schmc.ac.kr organization: Department of Internal Medicine, SoonChunHyang University School of Medicine, Digestive Disease Center and Research Institute, SoonChunHyang University Bucheon Hospital – sequence: 4 givenname: Young Kul surname: Jung fullname: Jung, Young Kul organization: Korea University Ansan Hospital – sequence: 5 givenname: Sae Hwan surname: Lee fullname: Lee, Sae Hwan organization: Soonchunhyang University College of Medicine Cheonan Hospital – sequence: 6 givenname: Moon Young surname: Kim fullname: Kim, Moon Young organization: Wonju Severance Christian Hospital – sequence: 7 givenname: Dae Won surname: Jun fullname: Jun, Dae Won organization: Hanyang University Hospital – sequence: 8 givenname: Jae Young surname: Jang fullname: Jang, Jae Young organization: Soonchunhyang University College of Medicine Seoul Hospital – sequence: 9 givenname: Jin Woo surname: Lee fullname: Lee, Jin Woo organization: Inha University Hospital – sequence: 10 givenname: Oh Sang surname: Kwon fullname: Kwon, Oh Sang organization: Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine |
| BackLink | https://cir.nii.ac.jp/crid/1870866216127104768$$DView record in CiNii https://www.ncbi.nlm.nih.gov/pubmed/34996920$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kstu1DAUhiNUREvpC7BAkWDRTcC3-LJBQiNKK1VCQsDWcpzjGVcZe7CTQbw9zqSUtotufP3_z-f4nJfVUYgBquo1Ru8xovJDZrhVskEEN4gSQRr8rDohiLUNoYQc3VsfV2c5-65sKVZIohfVMWVKcUXQSbX_BusE5T6GOrp68HtItfNditnn2oS-3sDOjNHCMEyDSbU1yfoQt6buYQ9D3G0hjLVxY_Fdrn7WkEzvrRln4G8_buqYzFBAo9_7w2pd9PlV9dyZIcPZ7Xxa_bj4_H112Vx__XK1-nTd2JarseEc-o5JKQCcdYxa4KrjSmGKhFOcct6BM61gTjrA0mHM2hb3qm2NkR1H9LS6Wrh9NDd6l_zWpD86Gq8PBzGttUmjtwNoYqiQPSatAcQIRworSsF1iPadMJQX1seFtZu6LfS25FESegB9eBP8Rq_jXkvBSMEVwPktIMVfE-RRb32eP9YEiFPWhGNJCJNYFOnbR9KbOKVQvmpWqVZiJlRRvbkf0V0o_8pbBGQR2FLPnMDdSTDScxvppY10aSN9aCM9hykfmawfDwUtWfnhaStdrLm8E9aQ_of9pOvd4grel7fmEUuBJOcEc0wERkxwSf8CQ5fnVw |
| CitedBy_id | crossref_primary_10_1038_s41575_024_01021_z crossref_primary_10_1097_TP_0000000000004401 crossref_primary_10_3390_life14030342 crossref_primary_10_4254_wjh_v14_i6_1120 crossref_primary_10_1002_mco2_70121 crossref_primary_10_1007_s10620_024_08754_6 crossref_primary_10_1016_j_jmii_2024_08_005 crossref_primary_10_1016_j_bbadis_2023_166750 crossref_primary_10_3390_v16101531 crossref_primary_10_3390_jcm12247547 crossref_primary_10_1080_14737167_2024_2348053 crossref_primary_10_1111_liv_16113 crossref_primary_10_3390_ijms25010268 crossref_primary_10_1007_s12072_024_10700_7 crossref_primary_10_3389_fmicb_2022_896588 crossref_primary_10_3390_medicina61091601 crossref_primary_10_3390_cells12172127 crossref_primary_10_1016_j_ijid_2025_108043 crossref_primary_10_3350_cmh_2024_0904 crossref_primary_10_1080_23744235_2025_2493370 crossref_primary_10_3390_life13091872 |
| Cites_doi | 10.1016/j.jhep.2017.07.025 10.1038/nrgastro.2016.60 10.1002/hep.24013 10.1016/j.jhep.2020.03.030 10.1016/j.jhep.2016.06.015 10.1002/hep.29707 10.1016/j.jhep.2019.10.005 10.1007/s10620-017-4749-x 10.1002/hep.21176 10.1016/j.cmi.2016.09.017 10.1111/jgh.14008 10.1016/j.jhep.2020.08.006 10.1016/j.jhepr.2020.100067 10.1053/gast.2002.33023 10.1016/j.jhep.2011.05.024 10.1111/jgh.14707 10.1016/j.jhep.2010.05.035 10.1093/cid/ciaa702 10.1053/j.gastro.2004.11.018 10.1002/hep.21178 10.1097/MEG.0000000000000964 10.1002/hep.20073 10.1053/jhep.2003.50346 10.3390/jcm8122065 10.1111/hiv.12705 10.1097/QAD.0000000000001966 10.1111/jvh.12578 10.1002/hep.28218 10.1016/j.cgh.2017.04.038 10.1016/j.jhep.2015.04.006 10.1016/j.cgh.2020.02.019 10.1016/j.cgh.2009.11.018 10.1053/j.gastro.2018.07.015 |
| ContentType | Journal Article |
| Contributor | Sae Hwan Lee Jun Yong Park Young Kul Jung Jae Young Jang Hae Won Yoo Sang Gyune Kim Park, Jun Yong Moon Young Kim Jin Woo Lee Dae Won Jun Oh Sang Kwon |
| Contributor_xml | – sequence: 1 fullname: Hae Won Yoo – sequence: 2 fullname: Jun Yong Park – sequence: 3 fullname: Sang Gyune Kim – sequence: 4 fullname: Young Kul Jung – sequence: 5 fullname: Sae Hwan Lee – sequence: 6 fullname: Moon Young Kim – sequence: 7 fullname: Dae Won Jun – sequence: 8 fullname: Jae Young Jang – sequence: 9 fullname: Jin Woo Lee – sequence: 10 fullname: Oh Sang Kwon – sequence: 11 fullname: Park, Jun Yong |
| Copyright | The Author(s) 2022 2022. The Author(s). The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | RYH C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.1038/s41598-021-03272-1 |
| DatabaseName | CiNii Complete Springer Nature OA/Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection Health & Medical Collection (Alumni Edition) Medical Database Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 2045-2322 |
| EndPage | 9 |
| ExternalDocumentID | oai_doaj_org_article_2a378d125ae0426091933efb03db7a36 PMC8742091 34996920 10_1038_s41598_021_03272_1 |
| Genre | Comparative Study Research Support, Non-U.S. Gov't Journal Article Observational Study |
| GeographicLocations | Seoul |
| GeographicLocations_xml | – name: Seoul |
| GrantInformation_xml | – fundername: Soonchunhyang University funderid: http://dx.doi.org/10.13039/501100002560 – fundername: Bristol-Myers Squibb funderid: http://dx.doi.org/10.13039/100002491 – fundername: ; |
| GroupedDBID | 0R~ 4.4 53G 5VS 7X7 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD AASML ABDBF ABUWG ACGFS ACUHS ADBBV ADRAZ AENEX AEUYN AFFHD AFKRA AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M1P M2P M48 M7P M~E NAO OK1 PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO RNT RNTTT RPM RYH SNYQT UKHRP 3V. 88A ACSMW AJTQC ALIPV M0L AAYXX CITATION CGR CUY CVF ECM EIF NPM 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c569t-66edb4887eefcf43ce69b6991307f96366befa574f8fe18f114551d955aa8b603 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 27 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000740510500017&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2045-2322 |
| IngestDate | Fri Oct 03 12:44:56 EDT 2025 Tue Nov 04 01:58:20 EST 2025 Thu Oct 02 10:15:23 EDT 2025 Tue Oct 07 09:19:39 EDT 2025 Mon Jul 21 05:13:26 EDT 2025 Sat Nov 29 02:51:07 EST 2025 Tue Nov 18 22:20:27 EST 2025 Fri Feb 21 02:40:31 EST 2025 Mon Nov 10 09:09:31 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2022. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c569t-66edb4887eefcf43ce69b6991307f96366befa574f8fe18f114551d955aa8b603 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0001-5086-5385 0000-0001-6324-2224 0000-0002-6566-1382 |
| OpenAccessLink | https://doaj.org/article/2a378d125ae0426091933efb03db7a36 |
| PMID | 34996920 |
| PQID | 2619581479 |
| PQPubID | 2041939 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_2a378d125ae0426091933efb03db7a36 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8742091 proquest_miscellaneous_2618224817 proquest_journals_2619581479 pubmed_primary_34996920 crossref_primary_10_1038_s41598_021_03272_1 crossref_citationtrail_10_1038_s41598_021_03272_1 springer_journals_10_1038_s41598_021_03272_1 nii_cinii_1870866216127104768 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-01-07 |
| PublicationDateYYYYMMDD | 2022-01-07 |
| PublicationDate_xml | – month: 01 year: 2022 text: 2022-01-07 day: 07 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Scientific Reports |
| PublicationTitleAbbrev | Sci Rep |
| PublicationTitleAlternate | Sci Rep |
| PublicationYear | 2022 |
| Publisher | Springer Science and Business Media LLC Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Springer Science and Business Media LLC – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | Lledo (CR27) 2018; 32 Degos (CR11) 2010; 53 Castera (CR12) 2005; 128 Sangiovanni (CR20) 2020; 73 CR17 CR16 Yoo (CR30) 2019; 8 Camma (CR4) 2004; 39 Knop (CR26) 2016; 23 Sangiovanni (CR1) 2006; 43 CR10 Facciorusso (CR29) 2018; 33 CR31 Martinez, Crespo, Navasa, Forns (CR7) 2011; 53 Conti (CR34) 2016; 65 Zarski (CR13) 2012; 56 Gotte, Feld (CR3) 2016; 13 CR2 Kronfli (CR28) 2020 Malin (CR33) 2019; 20 Poynard (CR5) 2002; 122 Carmona, Cordero, Ampuero, Rojas, Romero-Gomez (CR6) 2016; 22 CR8 Fernandes (CR24) 2019; 34 CR23 Li (CR22) 2018; 67 Chan (CR32) 2018; 63 Waziry (CR21) 2017; 67 Patel, Sebastiani (CR9) 2020; 2 Calvaruso, Craxi (CR19) 2020; 73 Wai (CR14) 2003; 38 Dolmazashvili (CR25) 2017; 29 Sterling (CR15) 2006; 43 Pons (CR18) 2020; 72 FF Fernandes (3272_CR24) 2019; 34 3272_CR2 F Conti (3272_CR34) 2016; 65 SM Martinez (3272_CR7) 2011; 53 RK Sterling (3272_CR15) 2006; 43 3272_CR23 M Gotte (3272_CR3) 2016; 13 J Chan (3272_CR32) 2018; 63 V Calvaruso (3272_CR19) 2020; 73 R Waziry (3272_CR21) 2017; 67 I Carmona (3272_CR6) 2016; 22 A Facciorusso (3272_CR29) 2018; 33 JJ Malin (3272_CR33) 2019; 20 CT Wai (3272_CR14) 2003; 38 N Kronfli (3272_CR28) 2020 E Dolmazashvili (3272_CR25) 2017; 29 JP Zarski (3272_CR13) 2012; 56 T Poynard (3272_CR5) 2002; 122 A Sangiovanni (3272_CR20) 2020; 73 C Camma (3272_CR4) 2004; 39 M Pons (3272_CR18) 2020; 72 JJ Yoo (3272_CR30) 2019; 8 A Sangiovanni (3272_CR1) 2006; 43 3272_CR31 3272_CR10 DK Li (3272_CR22) 2018; 67 F Degos (3272_CR11) 2010; 53 V Knop (3272_CR26) 2016; 23 K Patel (3272_CR9) 2020; 2 3272_CR16 3272_CR17 3272_CR8 L Castera (3272_CR12) 2005; 128 GM Lledo (3272_CR27) 2018; 32 |
| References_xml | – volume: 67 start-page: 1204 year: 2017 end-page: 1212 ident: CR21 article-title: Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression publication-title: J. Hepatol. doi: 10.1016/j.jhep.2017.07.025 – volume: 13 start-page: 338 year: 2016 end-page: 351 ident: CR3 article-title: Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights publication-title: Nat. Rev. Gastroenterol. Hepatol. doi: 10.1038/nrgastro.2016.60 – volume: 53 start-page: 325 year: 2011 end-page: 335 ident: CR7 article-title: Noninvasive assessment of liver fibrosis publication-title: Hepatology doi: 10.1002/hep.24013 – volume: 73 start-page: 593 year: 2020 end-page: 602 ident: CR20 article-title: Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis publication-title: J. Hepatol. doi: 10.1016/j.jhep.2020.03.030 – volume: 65 start-page: 727 year: 2016 end-page: 733 ident: CR34 article-title: Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals publication-title: J. Hepatol. doi: 10.1016/j.jhep.2016.06.015 – ident: CR2 – ident: CR16 – ident: CR10 – volume: 67 start-page: 2244 year: 2018 end-page: 2253 ident: CR22 article-title: The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study publication-title: Hepatology doi: 10.1002/hep.29707 – volume: 72 start-page: 472 year: 2020 end-page: 480 ident: CR18 article-title: Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals publication-title: J. Hepatol. doi: 10.1016/j.jhep.2019.10.005 – ident: CR8 – volume: 63 start-page: 486 year: 2018 end-page: 492 ident: CR32 article-title: Direct-acting antiviral therapy for chronic HCV infection results in liver stiffness regression over 12 months post-treatment publication-title: Dig. Dis. Sci. doi: 10.1007/s10620-017-4749-x – volume: 43 start-page: 1303 year: 2006 end-page: 1310 ident: CR1 article-title: The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients publication-title: Hepatology doi: 10.1002/hep.21176 – ident: CR23 – volume: 22 start-page: 839 year: 2016 end-page: 845 ident: CR6 article-title: Role of assessing liver fibrosis in management of chronic hepatitis C virus infection publication-title: Clin. Microbiol. Infect. doi: 10.1016/j.cmi.2016.09.017 – volume: 33 start-page: 942 year: 2018 end-page: 949 ident: CR29 article-title: Long-term liver stiffness assessment in hepatitis C virus patients undergoing antiviral therapy: Results from a 5-year cohort study publication-title: J. Gastroenterol. Hepatol. doi: 10.1111/jgh.14008 – volume: 73 start-page: 1548 year: 2020 end-page: 1556 ident: CR19 article-title: Hepatic benefits of HCV cure publication-title: J. Hepatol. doi: 10.1016/j.jhep.2020.08.006 – volume: 2 year: 2020 ident: CR9 article-title: Limitations of non-invasive tests for assessment of liver fibrosis publication-title: JHEP Rep. doi: 10.1016/j.jhepr.2020.100067 – volume: 122 start-page: 1303 year: 2002 end-page: 1313 ident: CR5 article-title: Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C publication-title: Gastroenterology doi: 10.1053/gast.2002.33023 – volume: 56 start-page: 55 year: 2012 end-page: 62 ident: CR13 article-title: Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: The ANRS HCEP-23 study publication-title: J. Hepatol. doi: 10.1016/j.jhep.2011.05.024 – volume: 34 start-page: 2187 year: 2019 end-page: 2195 ident: CR24 article-title: Effectiveness of direct-acting agents for hepatitis C and liver stiffness changing after sustained virological response publication-title: J. Gastroenterol. Hepatol. doi: 10.1111/jgh.14707 – volume: 53 start-page: 1013 year: 2010 end-page: 1021 ident: CR11 article-title: Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: A multicenter prospective study (the FIBROSTIC study) publication-title: J. Hepatol. doi: 10.1016/j.jhep.2010.05.035 – year: 2020 ident: CR28 article-title: Liver fibrosis in HIV-Hepatitis C virus (HCV) co-infection before and after sustained virologic response: what is the best non-invasive marker for monitoring regression? publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciaa702 – volume: 128 start-page: 343 year: 2005 end-page: 350 ident: CR12 article-title: Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C publication-title: Gastroenterology doi: 10.1053/j.gastro.2004.11.018 – volume: 43 start-page: 1317 year: 2006 end-page: 1325 ident: CR15 article-title: Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection publication-title: Hepatology doi: 10.1002/hep.21178 – ident: CR17 – volume: 29 start-page: 1223 year: 2017 end-page: 1230 ident: CR25 article-title: Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience publication-title: Eur. J. Gastroenterol. Hepatol. doi: 10.1097/MEG.0000000000000964 – volume: 39 start-page: 333 year: 2004 end-page: 342 ident: CR4 article-title: Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: A meta-analysis of individual patient data publication-title: Hepatology doi: 10.1002/hep.20073 – ident: CR31 – volume: 38 start-page: 518 year: 2003 end-page: 526 ident: CR14 article-title: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C publication-title: Hepatology doi: 10.1053/jhep.2003.50346 – volume: 8 start-page: 1 year: 2019 ident: CR30 article-title: The Influence of Histologic Inflammation on the Improvement of Liver Stiffness Values Over 1 and 3 Years publication-title: J Clin Med doi: 10.3390/jcm8122065 – volume: 20 start-page: 230 year: 2019 end-page: 236 ident: CR33 article-title: Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection publication-title: HIV Med. doi: 10.1111/hiv.12705 – volume: 32 start-page: 2347 year: 2018 end-page: 2352 ident: CR27 article-title: Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection publication-title: AIDS doi: 10.1097/QAD.0000000000001966 – volume: 23 start-page: 994 year: 2016 end-page: 1002 ident: CR26 article-title: Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy publication-title: J. Viral Hepat. doi: 10.1111/jvh.12578 – volume: 29 start-page: 1223 year: 2017 ident: 3272_CR25 publication-title: Eur. J. Gastroenterol. Hepatol. doi: 10.1097/MEG.0000000000000964 – volume: 72 start-page: 472 year: 2020 ident: 3272_CR18 publication-title: J. Hepatol. doi: 10.1016/j.jhep.2019.10.005 – volume: 32 start-page: 2347 year: 2018 ident: 3272_CR27 publication-title: AIDS doi: 10.1097/QAD.0000000000001966 – volume: 20 start-page: 230 year: 2019 ident: 3272_CR33 publication-title: HIV Med. doi: 10.1111/hiv.12705 – volume: 53 start-page: 1013 year: 2010 ident: 3272_CR11 publication-title: J. Hepatol. doi: 10.1016/j.jhep.2010.05.035 – volume: 128 start-page: 343 year: 2005 ident: 3272_CR12 publication-title: Gastroenterology doi: 10.1053/j.gastro.2004.11.018 – ident: 3272_CR16 doi: 10.1002/hep.28218 – volume: 34 start-page: 2187 year: 2019 ident: 3272_CR24 publication-title: J. Gastroenterol. Hepatol. doi: 10.1111/jgh.14707 – volume: 67 start-page: 2244 year: 2018 ident: 3272_CR22 publication-title: Hepatology doi: 10.1002/hep.29707 – volume: 63 start-page: 486 year: 2018 ident: 3272_CR32 publication-title: Dig. Dis. Sci. doi: 10.1007/s10620-017-4749-x – volume: 53 start-page: 325 year: 2011 ident: 3272_CR7 publication-title: Hepatology doi: 10.1002/hep.24013 – volume: 8 start-page: 1 year: 2019 ident: 3272_CR30 publication-title: J Clin Med doi: 10.3390/jcm8122065 – volume: 43 start-page: 1317 year: 2006 ident: 3272_CR15 publication-title: Hepatology doi: 10.1002/hep.21178 – volume: 38 start-page: 518 year: 2003 ident: 3272_CR14 publication-title: Hepatology doi: 10.1053/jhep.2003.50346 – ident: 3272_CR31 doi: 10.1016/j.cgh.2017.04.038 – volume: 122 start-page: 1303 year: 2002 ident: 3272_CR5 publication-title: Gastroenterology doi: 10.1053/gast.2002.33023 – volume: 33 start-page: 942 year: 2018 ident: 3272_CR29 publication-title: J. Gastroenterol. Hepatol. doi: 10.1111/jgh.14008 – volume: 56 start-page: 55 year: 2012 ident: 3272_CR13 publication-title: J. Hepatol. doi: 10.1016/j.jhep.2011.05.024 – ident: 3272_CR10 doi: 10.1016/j.jhep.2015.04.006 – volume: 65 start-page: 727 year: 2016 ident: 3272_CR34 publication-title: J. Hepatol. doi: 10.1016/j.jhep.2016.06.015 – volume: 13 start-page: 338 year: 2016 ident: 3272_CR3 publication-title: Nat. Rev. Gastroenterol. Hepatol. doi: 10.1038/nrgastro.2016.60 – volume: 43 start-page: 1303 year: 2006 ident: 3272_CR1 publication-title: Hepatology doi: 10.1002/hep.21176 – ident: 3272_CR8 doi: 10.1016/j.cgh.2020.02.019 – volume: 2 year: 2020 ident: 3272_CR9 publication-title: JHEP Rep. doi: 10.1016/j.jhepr.2020.100067 – volume: 23 start-page: 994 year: 2016 ident: 3272_CR26 publication-title: J. Viral Hepat. doi: 10.1111/jvh.12578 – ident: 3272_CR2 doi: 10.1016/j.cgh.2009.11.018 – year: 2020 ident: 3272_CR28 publication-title: Clin. Infect. Dis. doi: 10.1093/cid/ciaa702 – volume: 22 start-page: 839 year: 2016 ident: 3272_CR6 publication-title: Clin. Microbiol. Infect. doi: 10.1016/j.cmi.2016.09.017 – volume: 67 start-page: 1204 year: 2017 ident: 3272_CR21 publication-title: J. Hepatol. doi: 10.1016/j.jhep.2017.07.025 – ident: 3272_CR17 – volume: 73 start-page: 593 year: 2020 ident: 3272_CR20 publication-title: J. Hepatol. doi: 10.1016/j.jhep.2020.03.030 – volume: 39 start-page: 333 year: 2004 ident: 3272_CR4 publication-title: Hepatology doi: 10.1002/hep.20073 – ident: 3272_CR23 doi: 10.1053/j.gastro.2018.07.015 – volume: 73 start-page: 1548 year: 2020 ident: 3272_CR19 publication-title: J. Hepatol. doi: 10.1016/j.jhep.2020.08.006 |
| SSID | ssib045319080 ssib045319113 ssib045318930 ssib045319110 ssib045318929 ssib045318928 ssj0000529419 ssib045319075 |
| Score | 2.4818878 |
| Snippet | We prospectively investigated the changes of liver stiffness (LS) and the occurrence of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV)... Abstract We prospectively investigated the changes of liver stiffness (LS) and the occurrence of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV)... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer nii |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 193 |
| SubjectTerms | 692/4020/4021 692/699/1503/1607/1605 Administration Administration, Oral Aged Antiviral Agents Antiviral Agents - administration & dosage Antiviral Agents - adverse effects Antiviral drugs Carbamates Carbamates - administration & dosage Carcinoma Carcinoma, Hepatocellular Carcinoma, Hepatocellular - diagnosis Carcinoma, Hepatocellular - epidemiology Carcinoma, Hepatocellular - prevention & control Carcinoma, Hepatocellular - virology Chronic / diagnosis Chronic / drug therapy Chronic / epidemiology Chronic / virology Clinical trials Combination Drug Therapy Drug Therapy, Combination Elasticity Imaging Techniques Eradication Female Fibrosis Hepatitis C Hepatitis C, Chronic Hepatitis C, Chronic - diagnosis Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - epidemiology Hepatitis C, Chronic - virology Hepatocellular / diagnosis Hepatocellular / epidemiology Hepatocellular / prevention & control Hepatocellular / virology Hepatocellular carcinoma Humanities and Social Sciences Humans Imidazoles Imidazoles - administration & dosage Incidence Interferon Interferons Interferons - administration & dosage Isoquinolines Isoquinolines - administration & dosage Liver Liver cancer Liver Cirrhosis Liver Cirrhosis - diagnostic imaging Liver Cirrhosis - drug therapy Liver Cirrhosis - epidemiology Liver Cirrhosis - virology Liver Neoplasms Liver Neoplasms - diagnosis Liver Neoplasms - epidemiology Liver Neoplasms - prevention & control Liver Neoplasms - virology Male Medicine Middle Aged multidisciplinary Oral Patients Prospective Studies Pyrrolidines Pyrrolidines - administration & dosage Q R Retrospective Studies Ribavirin Ribavirin - administration & dosage Science Science (multidisciplinary) Seoul Sulfonamides Sulfonamides - administration & dosage Sustained Virologic Response Time Factors Treatment Outcome Valine Valine - administration & dosage Valine - analogs & derivatives |
| SummonAdditionalLinks | – databaseName: Biological Science Database dbid: M7P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BAYkL70egRUbiBlHjR2znVJWKqqeqQoB6i5zEbiOVpGy2lfj3zDjZrJZHL1xWq413Ze-MZ8bjme8DeOetD9rgIaeodJMqdGmp8yFPRfChqaVRmRrJJszxsT09LU6mhNswlVWubGI01E1fU458lyL93HJlir3LHymxRtHt6kShcRvuEEqCjKV7J3OOhW6xFC-mXplM2t0B_RX1lAmqIxJGpHzDH0XYfvQyXdv-LeL8s3Dyt9vT6JQOH_7vch7BgykcZfuj_jyGW757AvdGgsqfT-H6sz8bC2U71gd2QUUcLOAJux_agbmuYefozpY9pf-pnpXVRE3U9d8da9bVSCwSkbOjg2_ML1wzZQkZpYAZAQTgDxGHRXxHnV7DM_h6-OnLwVE6MTWkda6LZaq1byo0Bcb7UAcla69R9hh6ogUJuMW1rnxwuVHBBs9t4ASPzpsiz52zlc7kc9jq-s6_BEZwO7kK3FGLrcXjjzeVazBwcqoyvFIJ8JW8ynqCMSc2jYsyXqdLW44yLlHGZZRxyRN4P3_ncgTxuHH0R1KDeSQBcMcP-sVZOe3nUjhpbIPRofMR5L_AQFj6UGWEV-2kTmAHlQhnSK8cjaLVWmB0LQxhY2ibwPZKL8rJagzlWikSeDs_xv1OUnSd76_iGCr8tdwk8GLUxnmmEo-vuhBZAmZDTzeWsvmka88jprg1SuAiEviw0uj1tP79V726eRWv4b6gbhHKWJlt2FourvwO3K2vl-2weBP36i-7wkO_ priority: 102 providerName: ProQuest |
| Title | Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents |
| URI | https://cir.nii.ac.jp/crid/1870866216127104768 https://link.springer.com/article/10.1038/s41598-021-03272-1 https://www.ncbi.nlm.nih.gov/pubmed/34996920 https://www.proquest.com/docview/2619581479 https://www.proquest.com/docview/2618224817 https://pubmed.ncbi.nlm.nih.gov/PMC8742091 https://doaj.org/article/2a378d125ae0426091933efb03db7a36 |
| Volume | 12 |
| WOSCitedRecordID | wos000740510500017&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: Directory of Open Access Journals (DOAJ) customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M~E dateStart: 20110101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M7P dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: 7X7 dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: BENPR dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: PIMPY dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M2P dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9QwDLdgA2kviO8VtlOQeINqlzRN0kc2bRoPO1UToOOpStuEVRotut4m8d9jp73bjs8XXqyqTas0tms7tX8GeO2M80pjkJOVqo4lmrTYOp_GwjtfV4mWUzk0m9CzmZnPs_xWqy_KCRvggYeFOxA20aZGM2xdQFPP0ONInC-nBAxskwC2jV7PrWBqQPUWmeTZWCUzTcxBj5aKqskEZRAJLWK-YYkCYD_al7Zpfudr_poy-dN_02COTh7Cg9GPZO-G-T-CO659DPeHzpLfn8D1ufsyZLi2rPPskrIvmMfQuOubntm2Zhdoh5Yd7dtTIiqrqKdQ2321rL5JI2Khgzg7PfrE3MLW4_Yeo71bRpX9-CBqPhGOqESrfwofT44_HJ3GY4uFuEpVtoyVcnWJOqyd85WXSeUUMg19RlR9j7qpVOm8TbX0xjtuPCdcc15naWqtKdU0eQZbbde6XWCEk5NKzy3VxhqMW5wubY0ej5Wl5qWMgK-Wu6hG_HFqg3FZhP_giSkGFhXIoiKwqOARvFnf821A3_jr6EPi4nokIWeHEyhPxShPxb_kKYJ9lAGcIVGOXzOjlEC3WGgCtVAmgr2VdBSjuvcFhaGp4VJnEbxaX0ZFJS7a1nVXYQxl7BquI3g-CNN6pgnGnSoT0wj0hphtvMrmlba5CGDgRkuBLxHB25VA3kzrz0v14n8s1UvYEVQMQhtSeg-2losrtw_3qutl0y8mcFfPdaBmAtuHx7P8fBKUFOmZyIlqpNv5-7P88w_DYzvC |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VAoIL70egBSPBCaKuncR2DghBoWrVsqpQQb0FJ7HbSCUpm21R_xS_kRkn2dXy6K0HLtEq8Ua283ke9sx8AM-ttk4qdHLSXJZhjCotNNYloXDWlUWk4lHckU2o8Vjv76e7S_BzyIWhsMpBJnpBXTYF7ZGvkaWfaB6r9M3x95BYo-h0daDQ6GCxbc9-oMvWvt56j9_3hRAbH_bWN8OeVSAsEplOQyltmSNslbWucHFUWIn9RDMJ0e4QjlLm1plExU47y7XjVMqbl2mSGKNzOYrwvZfgMpoRQvtQwd3Zng6dmsU87XNzRpFea1E_Ug6boLgloUTIF_SfpwlArVZX1d8s3D8DNX87rfVKcOPm_zZ9t-BGb26zt936uA1Ltr4DVzsCzrO7cPrJHnSBwDVrHDuiIBXmqhynrmqZqUt2iOp62tDxBsXrsoKol-rmm2HlPNqKeaJ1trn-hdmJKftdUEZb3IwKIOCLiKPD_6JMtvYefL6QQd-H5bqp7UNgVE4oiR03lEKs0b2zKjclGoYmzhXP4wD4gI-s6Mu0E1vIUebDBSKddZjKEFOZx1TGA3g5-89xV6Tk3NbvCHazllRg3N9oJgdZL68yYSKlS7R-jfUkBika-pF1-YjqcZtIBrCKoMUe0pWj0NdSCvQehKLaH1IHsDLgMOulYpvNQRjAs9ljlGf0FU1tmxPfhgKbNVcBPOjQP-tphO65TMUoALWwLhaGsvikrg59zXStYoGDCODVsILm3fr3VD06fxRP4drm3sedbGdrvP0YrgvKjKHdObUCy9PJiV2FK8XptGonT7ycYPD1olfWL63voP4 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD4a4yJeuF8CGxgJniBq7SS284AQbFSbhqoKAdpbcBJ7izSS0XRD-2v8Os5x0lblsrc98FJVTRrZzndu9jnnA3hutXVSYZCT5rIMYzRpobEuCYWzriwiFQ_jjmxCjcd6fz-drMHPeS0MpVXOdaJX1GVT0B75gDz9RPNYpQPXp0VMtkdvjr-HxCBFJ61zOo0OInv27AeGb-3r3W181y-EGL3_tLUT9gwDYZHIdBZKacscIaysdYWLo8JKHDO6TIh8h9CUMrfOJCp22lmuHae23rxMk8QYncthhM-9BJcVNS33aYOTxf4OnaDFPO3rdIaRHrRoK6meTVAOk1Ai5Cu20FMGoIWrq-pv3u6fSZu_ndx6gzi6-T8v5S240bvh7G0nN7dhzdZ34GpHzHl2F04_2oMuQbhmjWNHlLzCXJXjMlYtM3XJDtGMzxo69qA8XlYQJVPdfDOsXGZhMU_Azna2vjA7NWW_O8po65tRYwR8EHF3-G9U4dbeg88XMun7sF43tX0IjNoMJbHjhkqLNYZ9VuWmRIfRxLnieRwAn2MlK_r27cQicpT5NIJIZx2-MsRX5vGV8QBeLv5z3DUvOffudwTBxZ3UeNz_0EwPsl6PZcJESpfoFRvryQ1SDAAi6_Ih9ek2kQxgEwGMI6RPjsZASykwqhCKeoJIHcDGHJNZry3bbAnIAJ4tLqOeo7doatuc-Hso4VlzFcCDThIWI40wbJepGAagVmRkZSqrV-rq0PdS1yoWOIkAXs2laTmsfy_Vo_Nn8RSuoUBlH3bHe4_huqCCGdq0UxuwPpue2E24UpzOqnb6xKsMBl8vWrB-AQGOqbs |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Regression+of+liver+fibrosis+and+hepatocellular+carcinoma+development+after+HCV+eradication+with+oral+antiviral+agents&rft.jtitle=Scientific+Reports&rft.au=Hae+Won+Yoo&rft.au=Jun+Yong+Park&rft.au=Sang+Gyune+Kim&rft.au=Young+Kul+Jung&rft.date=2022-01-07&rft.pub=Springer+Science+and+Business+Media+LLC&rft.eissn=2045-2322&rft.volume=12&rft_id=info:doi/10.1038%2Fs41598-021-03272-1 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |